Biological DMARDs and disease modification in axial spondyloarthritis

Funding Information: Competing interests AS: Consulting/speaking fees from MSD, UCB, Novartis. SR: Research grant from MSD; Consultancy/speaking fees from AbbVie, Eli Lilly, MSD, Novartis, UCB, Sanofi. DvdH: Consulting fees AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celg...

Full description

Bibliographic Details
Main Author: Sepriano, Alexandre (author)
Other Authors: Ramiro, Sofia (author), Van Der Heijde, Desirée (author), Landewé, Robert (author)
Format: review
Language:eng
Published: 2021
Subjects:
ankylosing
biological therapy
epidemiology
spondylitis
Immunology and Allergy
Rheumatology
Immunology
Online Access:http://hdl.handle.net/10362/124277
Country:Portugal
Oai:oai:run.unl.pt:10362/124277
Description
Summary:Funding Information: Competing interests AS: Consulting/speaking fees from MSD, UCB, Novartis. SR: Research grant from MSD; Consultancy/speaking fees from AbbVie, Eli Lilly, MSD, Novartis, UCB, Sanofi. DvdH: Consulting fees AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma Director of Imaging Rheumatology bv. RL: Consulting fees from AbbVie, BMS, Celgene, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Roche, UCB and is Director of Rheumatology Consultancy bv Publisher Copyright: ©

Similar Items